Latest news with #NASDAQ
Yahoo
18 minutes ago
- Business
- Yahoo
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., June 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,725 shares of its common stock and 27,790 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 34 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. The inducement grants were approved by PTC's Compensation Committee on June 16, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). All stock option awards have an exercise price of $51.87 per share, the closing price of PTC's common stock on June 16, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. ABOUT PTC THERAPEUTICS, is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit and follow on Facebook, X, and LinkedIn. For more information please contact: Investors:Ellen Cavaleri+1 (615) 618-8228ecavaleri@ Media:Jeanine Clemente+1 (908) 912-9406jclemente@ View original content to download multimedia: SOURCE PTC Therapeutics, Inc. Sign in to access your portfolio
Yahoo
21 minutes ago
- Business
- Yahoo
3 Stocks Under $10 with Open Questions
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn't mean they're bargains though, and we urge investors to be careful as many have risky business models. The bad behavior exhibited by lower-quality companies in this space can spook even the most seasoned professionals, which is why we started StockStory - to separate the good from the bad. Keeping that in mind, here are three stocks under $10 to avoid and some other investments you should consider instead. Share Price: $7.16 With courses ranging from investing to cooking to computer programming, Udemy (NASDAQ:UDMY) is an online learning platform that connects learners with expert instructors who specialize in a wide range of topics. Why Are We Wary of UDMY? Customer spending has dipped by 1.6% on average as it focused on growing its buyers Sales are projected to remain flat over the next 12 months as demand decelerates from its three-year trend High marketing expenses suggest it needs to spend heavily on new customer acquisition to sustain momentum Udemy's stock price of $7.16 implies a valuation ratio of 11.1x forward EV/EBITDA. Dive into our free research report to see why there are better opportunities than UDMY. Share Price: $0.74 Founded by two brothers, Purple (NASDAQ:PRPL) creates sleep and home comfort products such as mattresses, pillows, and bedding accessories. Why Should You Dump PRPL? Sales tumbled by 6.3% annually over the last two years, showing consumer trends are working against its favor Diminishing returns on capital from an already low starting point show that neither management's prior nor current bets are going as planned Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Purple is trading at $0.74 per share, or 24.6x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why PRPL doesn't pass our bar. Share Price: $1.33 Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. Why Should You Sell PACB? Sales trends were unexciting over the last two years as its 6.6% annual growth was below the typical healthcare company Free cash flow margin dropped by 29.9 percentage points over the last five years, implying the company became more capital intensive as competition picked up Short cash runway increases the probability of a capital raise that dilutes existing shareholders At $1.33 per share, PacBio trades at 2.4x forward price-to-sales. To fully understand why you should be careful with PACB, check out our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today
Business Wire
26 minutes ago
- Business
- Business Wire
Genasys Inc. Reports Increasing Demand for CONNECT in Wake of 'Signalgate'
SAN DIEGO--(BUSINESS WIRE)-- Genasys Inc. (NASDAQ: GNSS), the global leader In Protective Communications, today announced increasing interest and orders for CONNECT, the company's fully compliant, mission-critical communications platform for government and law enforcement. 'Greater demand for CONNECT has been spurred by the 'Signalgate' controversy, where several members of the federal government used the Signal messaging app for sensitive information sharing,' said Chief Jeff Halstead (Ret.), Genasys Senior Director of Strategic Accounts. 'Since the controversy, we are experiencing increasing demand for CONNECT information, demonstrations and orders from public safety leaders in small towns and large metro areas across the United States.' To date, strong order demand and contract renewals have grown CONNECT coverage in 41 states and more than 500 agencies, with other states and multiple agencies in deployment trials. 'Many public safety leaders now understand the importance and legal requirements of owning and controlling Interactions when planning and responding to crisis events,' Chief Halstead continued, 'During the last two weeks of national protests, I was contacted by more than a dozen police chiefs thanking me for helping them elevate their communication networks. Through CONNECT, many of them were able to regionally respond to mass protests in just a few minutes.' CONNECT Platform Advantages Heavily encrypted messaging from any device to all devices All messages and data are fully owned and controlled by the agency (Genasys has no access to data, chats, or information) Fortified Team chats where it is impossible for any person to be mistakenly added Nothing can be deleted or altered to maintain compliance Unlimited data sharing, photos, videos and documents Screenshot protection No push/share features prevent secure communications from being posted on social media All persons added to CONNECT are logged and tracked (they can only be added by sending an encrypted invitation directly to them) All data, chats and attachments are owned by the agency and can be easily reviewed in 30 seconds Complete transparency and accountability from all elected officials and law enforcement agencies Full compliance with FOIA, CJIS/FBI, public records retention laws and HIPAA Encrypted communications platforms like Signal are designed to allow users to hide or delete communications. Using CONNECT, a fully compliant encrypted communications platform specifically created for governmental operations, local, state, and federal governments/agencies can avoid the problems and fallout created by using non-FOIA-compliant consumer apps. About Genasys Inc. Genasys Inc. (NASDAQ: GNSS) is the global leader in Protective Communications. Incorporating the most comprehensive portfolio of preparedness, response, and analytics software and systems, as well as the Company's Long Range Acoustic Devices® (LRAD®) the Genasys Protect platform is designed around one premise: ensuring organizations and public safety agencies are 'Ready when it matters™.' Protecting people and saving lives for over 40 years, Genasys covers more than 155 million people in all 50 states and in over 100 countries worldwide. For more information, visit Forward-Looking Statements Except for historical information contained herein, the matters discussed are forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these statements. We base these statements on particular assumptions that we have made in light of our industry experience, the stage of product and market development as well as our perception of historical trends, current market conditions, current economic data, expected future developments and other factors that we believe are appropriate under the circumstances. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those suggested in any forward-looking statement. The risks and uncertainties in these forward-looking statements include without limitation the business impact of geopolitical conflicts and other causes that may affect our supply chain, and other risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. Risks and uncertainties are identified and discussed in our filings with the Securities and Exchange Commission. These forward-looking statements are based on information and management's expectations as of the date hereof. Future results may differ materially from our current expectations. For more information regarding other potential risks and uncertainties, see the 'Risk Factors' section of the Company's Form 10-K for the fiscal year ended September 30, 2024. Genasys Inc. disclaims any intent or obligation to publicly update or revise forward-looking statements, except as otherwise specifically stated.
Business Wire
32 minutes ago
- Business
- Business Wire
Campbell's Mourns the Death of Long-time Board Member Mary Alice Dorrance Malone
BUSINESS WIRE)-- The Campbell's Company (NASDAQ:CPB) and the company's Board of Directors mourn Mary Alice Dorrance Malone who recently passed away at the age of 75. Malone was the longest-tenured member of Campbell's Board of Directors with 35 years of service. Malone was the granddaughter of Dr. John T. Dorrance, the inventor of condensed soup and President of the company from 1914-1930, and the daughter of John T. Dorrance Jr., a former Chair of the company from 1962-1984. She was elected to the Board in 1990 and served with distinction on many of the board's standing committees, most recently on the Governance and Compensation & Organization committees. Keith R. McLoughlin, Chair of the Board, said, 'We are deeply saddened by the passing of Mary Alice. As a descendent of the company's founder and a significant long-term shareholder, her contributions to grow and protect Campbell's legacy were immeasurable. She will be missed in our board meetings and as a friend and colleague. On behalf of my fellow board members, we extend our heartfelt condolences to her family and friends.' Malone was an entrepreneur, a private investor, and a philanthropist, having served for many years on the boards of several nonprofit organizations and actively participated in many philanthropic endeavors. Her passion and primary business were equestrian sports. She was President of Iron Spring Farm horse breeding and performance centers in Pennsylvania and Florida, which she founded in 1976. Mick Beekhuizen, Campbell's President and Chief Executive Officer, said, 'Mary Alice was a highly committed director and helped guide the company through many chapters. Her extensive knowledge of Campbell's history, organization and culture, and her love for our food and iconic brands were invaluable to management and the board. Her positive impact on the company will last for generations to come. Everyone at Campbell's offers our deepest condolences to her loved ones.' Malone is survived by two daughters. Funeral arrangements are not public. The family respectfully requests privacy during this time of mourning. The board will be considering the election of a new member. About The Campbell's Company For 155 years, The Campbell's Company (NASDAQ:CPB) has been connecting people through food they love. Headquartered in Camden, N.J. since 1869, generations of consumers have trusted Campbell's to provide delicious and affordable food and beverages. Today, the company is a North American focused brand powerhouse, generating fiscal 2024 net sales of $9.6 billion across two divisions: Meals & Beverages and Snacks. The Campbell's portfolio of 16 leadership brands includes: Campbell's, Cape Cod, Chunky, Goldfish, Kettle Brand, Lance, Late July, Pace, Pacific Foods, Pepperidge Farm, Prego, Rao's, Snack Factory pretzel crisps, Snyder's of Hanover, Swanson and V8. For more information, visit
Business Wire
32 minutes ago
- Business
- Business Wire
Lineage Streamlines Import Process with Newly Certified Customs Bonded Warehouse Space in Seattle
NOVI, Mich.--(BUSINESS WIRE)--Lineage, Inc. (NASDAQ: LINE) (the 'Company'), the world's largest global temperature-controlled warehouse REIT, today announced that its Seattle – Garfield facility, located at the Port of Seattle, is now an approved Class 3 Public bonded storage facility. This is Lineage's first customs bonded facility in the state of Washington and one of the first refrigerated storage facilities with customs bonded space in the Seattle market. With this new certification, the site is now better equipped to help customers navigate the complexities of international logistics, enabling greater precision, flexibility and ease by providing safe temperature-controlled storage of imported goods under U.S. Customs and Border Protection (CBP) supervision until they are cleared for domestic commerce or re-export. These services provide a crucial gateway for temperature-sensitive imports arriving via the Port of Seattle. Located at 2001 W Garfield Street on Pier 90, Lineage's Seattle – Garfield facility offers cold storage, drayage, temperature-controlled rail and on-demand trucking. The new customs bonded warehousing service complements the site's existing USDA and FDA inspections, drayage and intermodal services, strengthening Lineage's ability to help make the import process easier and more streamlined for customers. 'Our certified customs bonded warehouse space in Seattle marks an exciting milestone for Lineage, reflecting our commitment to anticipate and meet customer needs in a dynamic global trade environment,' said Brian Beattie, President, North America West, at Lineage. 'By expanding our import service capabilities in a critical hub for global trade, we aim to offer our customers greater flexibility to respond to shifting market conditions while maintaining compliance and protecting product integrity.' The Seattle – Garfield facility joins Lineage's growing network of bonded warehouses and I-Houses in key markets across the U.S. strategically positioned for global connectivity. The company now operates 10 bonded warehouse locations and 42 USDA-approved I-House facilities nationwide, streamlining both regulatory compliance and import logistics for food shippers. To learn more about Lineage's global facility network and integrated transportation solutions, visit About Lineage Lineage, Inc. (NASDAQ: LINE) is the world's largest global temperature-controlled warehouse REIT with a network of over 480 strategically located facilities totaling over 84 million square feet and approximately 3.0 billion cubic feet of capacity across countries in North America, Europe, and Asia-Pacific. Coupling end-to-end supply chain solutions and technology, Lineage partners with some of the world's largest food and beverage producers, retailers, and distributors to help increase distribution efficiency, advance sustainability, minimize supply chain waste, and, most importantly, feed the world. Learn more at and join us on LinkedIn, Facebook, Instagram, and X. Forward Looking Statements Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Lineage intends for all such forward-looking statements to be covered by the applicable safe harbor provisions for forward-looking statements contained in those acts. Such forward-looking statements can generally be identified by Lineage's use of forward-looking terminology such as 'may,' 'will,' 'expect,' 'intend,' 'anticipate,' 'estimate,' 'believe,' 'continue,' 'seek,' 'objective,' 'goal,' 'strategy,' 'plan,' 'focus,' 'priority,' 'should,' 'could,' 'potential,' 'possible,' 'look forward,' 'optimistic,' or other similar words. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Such statements are subject to certain risks and uncertainties, including known and unknown risks, which could cause actual results to differ materially from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of Lineage's performance in future periods. Except as required by law, Lineage does not undertake any obligation to update or revise any forward-looking statements contained in this release.
